SIRT1 Direct Fluorescent Screening Assay Kit

Item No. 10010401

www.caymanchem.com
Customer Service 800.364.9897
Technical Support 888.526.5351
1180 E. Ellsworth Rd · Ann Arbor, MI · USA

TABLE OF CONTENTS

GENERAL INFORMATION
3 Materials Supplied
4 Safety Data
4 Precautions
5 If You Have Problems
5 Storage and Stability
5 Materials Needed but Not Supplied

INTRODUCTION
6 Background
8 About This Assay

PRE-ASSAY PREPARATION
10 Reagent Preparation

ASSAY PROTOCOL
11 Plate Set Up
13 Performing the Assay

ANALYSIS
15 Calculations
16 Performance Characteristics
17 Interferences

RESOURCES
19 Troubleshooting
20 References
22 Plate Template
23 Notes
23 Warranty and Limitation of Remedy

GENERAL INFORMATION

Materials Supplied

Item Number	Item	Quantity
10010993	SIRT1 Direct Assay Buffer (10X)	1 vial
10010994	SIRT1 (human recombinant)	2 vials
10010995	SIRT1 Direct Peptide	2 vials
10010996	SIRT1 Direct NAD^+	1 vial
10010997	SIRT1 Direct Nicotinamide	1 vial
10010998	SIRT1 Direct Developer	1 vial
10010999	SIRT1 Direct Fluorophore	1 vial
10011288	Half Volume 96-Well Plate (white)	1 plate
400012	96-Well Cover Sheet	1 cover

If any of the items listed above are damaged or missing, please contact our Customer Service department at (800) 364-9897 or (734) 971-3335. We cannot accept any returns without prior authorization.

Sold under license from CycLex® Co., Ltd (Patent Nos. EP 1243658, US 7033778, US 7256013, and JP 4267043).

WARNING: THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Safety Data

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent *via* email to your institution.

Precautions

Please read these instructions carefully before beginning this assay.

If You Have Problems

Technical Service Contact Information

Phone: 888-526-5351 (USA and Canada only) or 734-975-3888

Fax: 734-971-3641

Email: techserv@caymanchem.com

Hours: M-F 8:00 AM to 5:30 PM EST

In order for our staff to assist you quickly and efficiently, please be ready to supply the lot number of the kit (found on the outside of the box).

Storage and Stability

This kit will perform as specified if stored at -80°C and used before the expiration date indicated on the outside of the box.

Materials Needed But Not Supplied

1. A fluorometer with the capacity to measure fluorescence using excitation wavelength of 350-360 and emission wavelength of 450-465 nm.
2. Adjustable pipettes and a repeating pipettor.
3. A source of pure water; glass distilled water or HPLC-grade water is acceptable.

INTRODUCTION

Background

Nucleosomes, which fold chromosomal DNA, contain two molecules each of the core histones H2A, H2B, H3, and H4. Almost two turns of DNA are wrapped around this octameric core, which represses transcription.[1] The histone amino termini extend from the core, where they can be post-translationally modified by acetylation, phosphorylation, ubiquitination, and methylation, affecting their charge and function. Acetylation of the ε-amino groups of specific histone lysines is catalyzed by histone acetyltransferases (HATs) and correlates with an open chromatin structure and gene activation. Histone deacetylases (HDACs) catalyze the hydrolytic removal of these acetyl groups from histone lysine residues and correlates with chromatin condensation and transcriptional repression.[2,3]

The sirtuins represent a distinct class of trichostatin A-insensitive lysyl-deacetylases (class III HDACs) and have been shown to catalyze a reaction that couples lysine deacetylation to the formation of nicotinamide and O-acetyl-ADP-ribose from NAD^+ and the abstracted acetyl group.[4-6] There are seven human sirtuins which have been designated SIRT1-SIRT7.[7] SIRT1, which is located in the nucleus, is the human sirtuin with the greatest homology to yeast Silent information regulator 2 (Sir2) and has been shown to regulate the activity of the p53 tumor suppressor and inhibit apoptosis.[8-10] These results have significant implications regarding an important role of SIRT1 in modulating the sensitivity of cells in p53-dependent apoptotic response and the possible effect in cancer therapy. Since the growth suppressive function of p53 is strongly enhanced by DNA damaging reagents, it is expected that inhibitors of SIRT1 may be effective anticancer drugs.[11,12]

Recent screens for modulators of SIRT1 activity yielded a number of small molecule activators. Several of these activating compounds extended yeast, *D. melanogaster*, and *C. elegan* lifespans in a way that mimicked caloric restriction.[13,14] Resveratrol, the most potent of these compounds, activated SIRT1 in human cells and enhanced the survival rate of cells stressed by irradiation.[13] However, this activation of SIRT1 is under the subject of debate. It was determined that the *in vitro* activation of SIRT1 and Sir2 by resveratrol was a substrate-specific event (*i.e.*, the binding of resveratrol to SIRT1 promoted a conformational change that better accommodated the attached coumarin group in the peptide substrate.)[15,16] Additional research needs to be done to further elucidate the mechanism behind SIRT1 activation, as well as to establish the role of SIRT1 activation in aging, cancer, and neurodegenerative disease.[17,18]

About This Assay

Cayman's SIRT1 Direct Screening Assay Kit provides a convenient fluorescence-based method for screening SIRT1 inhibitors or activators. The procedure requires only two easy steps, both performed in the same microplate (Figure 1). In the first step, the substrate, which comprises the p53 sequence Arg-His-Lys-Lys(ε-acetyl)-AMC, is incubated with human recombinant SIRT1 along with its cosubstrate NAD^+. Deacetylation sensitizes the substrate such that treatment with the developer in the second step releases a fluorescent product. The fluorophore can be easily analyzed using an excitation wavelength of 350-360 nm and an emission wavelength of 450-465 nm.



Figure 1.

Reagent Preparation

1. **SIRT1 Direct Assay Buffer (10X) - (Item No. 10010993)**

   Dilute 3 ml of Assay Buffer concentrate with 27 ml of HPLC-grade water. This final Buffer (50 mM Tris-HCl, pH 8.0, containing 137 mM NaCl, 2.7 mM KCl, and 1 mM $MgCl_2$) should be used in the assay and for diluting reagents. When stored at 4°C, this diluted buffer is stable for at least six months.

2. **SIRT1 (human recombinant) - (Item No. 10010994)**

   Each vial contains 100 µl of human recombinant SIRT1. Thaw the enzyme on ice, add 300 µl of diluted Assay Buffer to the vial, and vortex. The diluted enzyme is stable for four hours on ice. One vial of enzyme is enough SIRT1 to assay 80 wells. Use the additional vial if assaying the entire plate.

3. **SIRT1 Direct Peptide - (Item No. 10010995)**

   Each vial contains 100 µl of a 5 mM peptide solution comprising amino acids 379-382 of human p53 conjugated to aminomethylcoumarin (AMC). It is ready to use to make the substrate solution.

4. **SIRT1 Direct NAD^+ - (Item No. 10010996)**

   The vial contains 500 µl of a 50 mM solution of NAD^+. It is ready to use to make the substrate solution.

5. **SIRT1 Direct Nicotinamide - (Item No. 10010997)**

   The vial contains 500 µl of a 50 mM solution of nicotinamide, a sirtuin inhibitor. It is ready to use to make the Stop/Developing Solution.

6. **SIRT1 Direct Developer - (Item No. 10010998)**

   The vial contains the SIRT1 developer.

7. **SIRT1 Direct Fluorophore - (Item No. 10010999)**

   The vial contains 50 µl of 10 mM 7-amino-4-methylcoumarin in DMSO. The fluorophore can be used to assay for interference (see page 17).

Plate Set Up

There is no specific pattern for using the wells on the plate. However, it is necessary to have three wells designated as 100% initial activity and three wells designated as background wells. We suggest that each inhibitor/activator sample be assayed in triplicate and that you record the contents of each well on the template sheet provided on page 22. A typical layout of samples and compounds to be measured in triplicate is given in Figure 2.

	1	2	3	4	5	6	7	8	9	10	11	12
A	BW	BW	BW	7	7	7	15	15	15	23	23	23
B	A	A	A	8	8	8	16	16	16	24	24	24
C	1	1	1	9	9	9	17	17	17	25	25	25
D	2	2	2	10	10	10	18	18	18	26	26	26
E	3	3	3	11	11	11	19	19	19	27	27	27
F	4	4	4	12	12	12	20	20	20	28	28	28
G	5	5	5	13	13	13	21	21	21	29	29	29
H	6	6	6	14	14	14	22	22	22	30	30	30

BW - Background Wells
A - 100% Initial Activity Wells
1-30 - Inhibitor/Activator Wells

Figure 2. Sample plate format

Pipetting Hints

- It is recommended that an adjustable pipette be used to deliver reagents to the wells.
- Before pipetting each reagent, equilibrate the pipette tip in that reagent (*i.e.*, slowly fill the tip and gently expel the contents, repeat several times).
- Do not expose the pipette tip to the reagent(s) already in the well.

General Information

- The final volume of the assay is 100 µl in all the wells.
- Use the diluted Assay Buffer in the assay.
- All reagents except SIRT1 and Stop/Developing Solution must be equilibrated to room temperature before beginning the assay.
- It is not necessary to use all the wells on the plate at one time.
- If the appropriate inhibitor/activator dilution is not known, it may be necessary to assay at several dilutions.
- We recommend assaying samples in triplicate, but it is the user's discretion to do so.
- Thirty inhibitor/activator samples can be assayed in triplicate or forty-six in duplicate.
- The assay temperature is 22-25°C.
- Monitor the fluorescence on a fluorometer with an excitation wavelength of 350-360 nm and an emission wavelength of 450-465 nm.

Performing the Assay

1. **Preparation of Substrate solution -** To one of the thawed SIRT1 peptide vials (Item No. 10010995), add 240 µl of NAD^+ solution (Item No. 10010996), and 850 µl of diluted Assay Buffer. One vial of peptide will make enough substrate solution for 79 wells. The substrate solution is stable for six hours. The addition of 15 µl to the assay yields a final concentration of 125 µM peptide and 3 mM NAD^+. *NOTE: The K_m values for the peptide and NAD^+ are 200 and 435 µM, respectively.*
2. **100% Initial Activity Wells -** add 25 µl of Assay Buffer, 5 µl of diluted SIRT1, and 5 µl of solvent (the same solvent used to dissolve the inhibitor/activator) to three wells.
3. **Background Wells -** add 30 µl of Assay Buffer and 5 µl of solvent (the same solvent used to dissolve the inhibitor/activator) to three wells.
4. **Inhibitor/Activator Wells -** add 25 µl of Assay Buffer, 5 µl of diluted SIRT1, and 5 µl of inhibitor/activator* to three wells.
5. Initiate the reactions by adding 15 µl of Substrate Solution to all the wells being used.
6. Cover the plate with the plate cover and incubate on a shaker for 45 minutes at room temperature.
7. **Preparation of Stop/Developing Solution -** Weigh 30 mg of Developer (Item No. 10010998) into a vial that will hold 5 ml then add 200 µl of Nicotinamide (Item No. 10010997) and 4.8 ml of diluted Assay Buffer. Vortex until the Developer is into solution. This is enough Stop/Developing Solution for the entire plate. The Stop/Developing Solution is stable for four hours on ice.
8. Remove the plate cover and add 50 µl of Stop/Developing Solution to each well. Cover the plate with the plate cover and incubate for 30 minutes at room temperature.

9. Remove the plate cover and read the plate in a fluorometer using an excitation wavelength of 350-360 nm and an emission wavelength of 450-465 nm. It may be necessary to adjust the gain setting on the instrument to allow for the measurement of all the samples. The fluorescence is stable for 30 minutes.

*Test compounds should be dissolved in Assay Buffer whenever possible. Alternatively, compounds may be prepared in DMSO as long as the final concentration in the assay is <2%. If another organic solvent is used, experiments must be performed to test for solvent effects.

ANALYSIS

Calculations

1. Determine the average fluorescence of each sample.
2. Subtract the fluorescence of the background wells from the fluorescence of the 100% initial activity and the inhibitor/activator wells.
3. Determine the percent inhibition/activation for each sample. To do this, subtract each inhibitor/activator sample value from the 100% initial activity sample value. Divide the result by the 100% initial activity value and then multiply by 100 to give the percent inhibition/activation.
4. Either graph the Percent Inhibition or Percent Initial Activity as a function of the inhibitor concentration to determine the IC_{50} value (concentration at which there was 50% inhibition). An example of SIRT1 inhibition by Sirtinol, a sirtuin-specific inhibitor, is shown in Figure 3 on page 16.[19,20]

$$\text{\% Inhibition/Activation} = \left[\frac{\text{Initial Activity - Sample}}{\text{Initial Activity}}\right] \times 100$$

Performance Characteristics



Figure 3. Inhibition of SIRT1 by Sirtinol (IC_{50} = 38 µM)

Precision:

When a series of sixteen SIRT1 measurements were performed on the same day, the intra-assay coefficient of variation was 2.5%. When a series of sixteen SIRT1 measurements were performed on five different days under the same experimental conditions, the inter-assay coefficient of variation was 4.3%.

Interferences

It is possible that a compound tested for SIRT1 inhibition/activation will interfere with the development of the assay or interfere with the fluorophore. Potential fluorophore interference can be tested by assaying the compound in question with the fluorophore. A procedure is outlined below.

Testing for Fluorophore Interference

1. Dilute 20 µl of Fluorophore (Item No. 10010999) with 480 µl of diluted Assay Buffer.
2. **Fluorophore wells** - add 5 µl of diluted Fluorophore, 5 µl of solvent (the same solvent used to dissolve the compound), and 90 µl of diluted Assay Buffer to three wells.
3. **Compound wells** - add 5 µl of diluted Fluorophore, 5 µl of compound, and 90 µl of diluted Assay Buffer to three wells.
4. Cover the plate with the plate cover and incubate for 10 minutes at room temperature.
5. Remove the plate cover and read the plate in a fluorometer using an excitation wavelength of 350-360 nm and an emission wavelength of 450-465 nm. It may be necessary to adjust the gain setting on the instrument to allow for the measurement of all the samples.

Calculating the Percent Fluorophore Interference

1. Determine the average fluorescence of each sample.
2. Determine the percent interference for the compound. To do this, subtract each compound value from the fluorophore value. Divide the result by the fluorophore value and then multiply by 100 to give the percent interference. The percent interference should be less than 10% for the compound to be not affecting the fluorophore.

Testing for Developer Interference

1. **SIRT1 wells -** add 25 µl of Assay Buffer and 5 µl of diluted SIRT1 to three wells.
2. **Compound wells -** add 25 µl of Assay Buffer and 5 µl of diluted SIRT1 to three wells.
3. Initiate the reactions by adding 15 µl of Substrate Solution to all the wells being used.
4. Cover the plate with the plate cover and incubate on a shaker for 45 minutes at room temperature
5. Remove the plate cover and add 50 µl of Stop/Developing Solution to the SIRT1 and compound wells.
6. Add 5 µl of compound to the compound wells and 5 µl of solvent (the same solvent used to dissolve the compound) to the SIRT1 wells.
7. Cover the plate with the plate cover and incubate for 30 minutes at room temperature.
8. Remove the plate cover and read the plate in a fluorometer using an excitation wavelength of 350-360 nm and an emission wavelength of 450-465 nm. It may be necessary to adjust the gain setting on the instrument to allow for the measurement of all the samples.

Calculating the Percent Developer Interference

1. Determine the average fluorescence of each sample.
2. Determine the percent interference for the compound. To do this, subtract each compound value from the SIRT1 value. Divide the result by the SIRT1 value and then multiply by 100 to give the percent interference. The percent interference should be less than 10% for the compound to be not affecting the developer.

RESOURCES

Troubleshooting

Problem	Possible Causes	Recommended Solutions
Erratic values; dispersion of duplicates/triplicates	A. Poor pipetting/technique B. Bubble in the well(s)	A. Be careful not to splash the contents of the wells B. Carefully tap the side of the plate with your finger to remove bubbles
No Fluorescence detected above background in any of the wells	Either SIRT1 or stop solution was not added to the wells	Make sure to add all the components to the wells and re-assay
The fluorometer exhibited 'MAX' values for the wells	The GAIN setting is too high	Reduce the GAIN and re-read
No inhibition/activation seen with compound	A. The compound concentration is not high enough B. The compound is not an inhibitor/activator of the enzyme	Increase the compound concentration and re-assay

References

1. Grunstein, M. *Nature* **389**, 349-352 (1997).
2. Strahl, B.D. and Allis, D. *Nature* **403**, 41-45 (2000).
3. Cheung, W.L., Briggs, D.B., and Allis, C.D. *Curr. Opin. Cell Biol.* **12**, 326-333 (2000).
4. Imai, S.-I., Armstrong, C.M., Kaeberlein, M., *et al. Nature* **403**, 795-800 (2000).
5. Tanner, K.G., Landry, J., Sternglanz, R., *et al. Proc. Natl. Acad. Sci. USA* **97(26)**, 14178-14182 (2000).
6. Tanny, J. C., Moazed, D. *Proc. Natl. Acad. Sci. USA* **98(2)**, 415-420 (2001).
7. Frye, R.A. *Biochem. Biophys. Res. Commun.* **273**, 793-798 (2000).
8. Luo, J., Nikolaev, A.Y., Imai, S.-I., *et al. Cell* **107**, 137-148 (2001).
9. Vaziri, H., Dessain, S.K., Eaton, E.N., *et al. Cell* **107**, 149-159 (2001).
10. Langley, E., Pearson, M., Faretta, M., *et al. EMBO J.* **21(10)**, 2383-2396 (2002).
11. Longo, V.D. and Kennedy, B.K. *Cell* **126**, 257-268 (2006).
12. Saunders, L.R., Verdin, E. *Oncogene* **26**, 5489-5504 (2007).
13. Howitz, K.T., Bitterman, K.J., Cohen, H.Y., *et al. Nature* **425**, 191-196 (2003).
14. Wood, J.G., Rogina, B., Lavu, S., *et al. Nature* **430**, 686-689 (2004).
15. Borra, M.T., Smith, B.C., and Denu, J.M. *J. Biol. Chem.* **280(17)**, 17187-17195 (2005).
16. Kaeberlein, M., McDonagh, T., Heltweg, B., *et al. J. Biol. Chem.* **280(17)**, 17038-17045 (2005).
17. Yamamoto, H., Schoonjans, K., Auwerx, J. *Mol. Endocrinol.* **21(8)**, 1745-1755 (2007).
18. Westphal, C.H., Dipp, M.A., Guarente, L. *Trends Biochem. Sci.* **32(12)**, 555-560 (2007).
19. Grozinger, C.M., Chao, E.D., Blackwell, H.E., *et al. J. Biol. Chem.* **276(42)**, 38837-38843 (2001).
20. Denu, J.M. *Current Opinion in Chemical Biology* **9**, 431-440 (2005).

	A	B	C	D	E	F	G	H
12								
11								
10								
9								
8								
7								
6								
5								
4								
3								
2								
1								

NOTES

Warranty and Limitation of Remedy

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

This document is copyrighted. All rights are reserved. This document may not, in whole or part, be copied, photocopied, reproduced, translated, or reduced to any electronic medium or machine-readable form without prior consent, in writing, from Cayman Chemical Company.

©08/02/2016, Cayman Chemical Company, Ann Arbor, MI, All rights reserved. Printed in U.S.A.